| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-048 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于不向下修正"洁特转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 因公司实施 2024 年年度权益分派方案，"洁特转债"的转股价格自 2025 年 7 月 2 日起由 48.02 元/股调整为 47.95 元/股，具体内容详见公司于 2025 年 6 月 25 日披露的《关于实施 2024 年年度权益分派时调整"洁特转债"转股价格的公告》 （公告编号：2025-037）。 重要内容提示： 一、转股价格调整/修正依据 （一）"洁特转债"基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，广州洁特生物过滤股份有限公司（以下简称"公司"）向不特定对象共计发 行 440.00 万张，每 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-047 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届董事会第二十二次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十二 次会议于 2025 年 8 月 1 日以现场及通讯相结合方式召开，会议通知已于 2025 年 7 月 25 日通过通讯方式送达全体董事。本次会议由董事长袁建华先生召集并主 持，应参加董事 7 人，实际参加表决董事 7 人。本次会议的召集、召开和表决程 序均符合国家有关法律、法规及《公司章程》等有关规定。经全体董事一致同 意，形成决议如下： 一、以 4 票同意，0 票反对，0 票弃权，审议通过了《关于不向下修正"洁 特转债"转股价格的议案》，关联董事袁建华、Yuan Ye James、Dannie Yuan 回避表决。 董事会同意本次不向下修正转股价格，同时在未 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-046 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于"洁特转债"预计满足转股价格修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 可转债代码：118010 可转债简称：洁特转债 转股价格：47.95 元/股 转股期限：2023 年 1 月 4 日至 2028 年 6 月 27 日 经上海证券交易所自律监管决定书（[2022]203 号文）同意，公司 44,000.00 万元可转债于 2022 年 8 月 2 日起在上海证券交易所挂牌交易，债券简称"洁特 转债"，债券代码"118010"。 根据有关规定及《广州洁特生物过滤股份有限公司向不特定对象发行可转换 公司债券证券募集说明书》（以下简称"《募集说明书》"）的约定，公司本次发行 的"洁特转债"自 2023 年 1 月 4 日起可转换为公司股份，初始转股价格为 48.2 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd, indicating a strategic move in the company's ownership structure and potential implications for future governance and investment. Group 1: Shareholder Information - The shareholder, Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership), held 1,396,950 shares, representing 1.00% of the company's total share capital prior to the reduction plan [2]. - The shares were acquired before the company's IPO and through capital reserve conversion, with the lock-up period lifted on January 30, 2023, allowing for trading [2]. Group 2: Reduction Plan Implementation - The shareholder planned to reduce holdings by up to 186,315 shares, which is 0.1327% of the total share capital, through centralized bidding [3]. - As of July 10, 2025, the shareholder successfully reduced their holdings by 186,315 shares, fully aligning with the previously disclosed reduction plan [3][4]. - The reduction was confirmed to have met the planned minimum reduction quantity, and the plan was not terminated early [4].

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd, indicating a strategic move in the company's shareholder structure and potential implications for future stock performance [1][2]. Shareholder Holding Situation - Before the reduction plan, the shareholder Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership) held 1,396,950 shares, accounting for 1.00% of the company's total share capital [1]. - The shares were acquired prior to the company's IPO and through capital reserve conversion, with the lock-up period lifted on January 30, 2023 [1]. Reduction Plan Implementation Results - As of July 10, 2025, the shareholder had reduced their holdings by 186,315 shares, representing 0.1327% of the total share capital [2]. - The reduction was executed through centralized bidding, with a total amount of approximately 3,098,815.23 yuan, at a price range of 16.49 to 16.85 yuan per share [2]. - Following the reduction, the shareholder's remaining shares totaled 1,210,635, which is 0.86% of the total share capital [2]. Consistency with Previous Disclosures - The actual reduction aligns with the previously disclosed reduction plan, confirming that the planned reduction was fully executed [2].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-045 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持计划实施前，股东广州萝岗区汇资投资管理合伙企业（有限合伙） （以下简称"汇资投资"）持有广州洁特生物过滤股份有限公司（以下简称"公司"） 股份 1,396,950 股，占公司总股本 1.00%。上述股份来源为公司 IPO 前取得的及 通过资本公积转增股本取得的股份，已于 2023 年 1 月 30 日解除限售并上市流通。 减持计划的实施结果情况 公司于 2025 年 6 月 10 日披露了《股东减持股份计划公告》（公告编号： 2025-033）。汇资投资拟通过集中竞价方式减持股份数量不超过 186,315 股，占公 司总股本不超过 0.1327%。截至本公告日，汇资投资通过集中竞价交易方式已累 计减持 1 ...

Summary of Key Points Core Viewpoint - The company has established a special account for the management and use of raised funds, ensuring investor protection and compliance with regulatory requirements [1][2][3]. Fundraising Basic Information - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB, which has been verified by Tianjian Accounting Firm [1]. Special Account Establishment - A special account for raised funds has been set up to temporarily supplement working capital, with a limit of 200 million RMB, effective for up to 12 months from December 30, 2024 [2][3]. Three-Party Supervision Agreement - The company signed a three-party supervision agreement with the underwriter and the bank to regulate the management of raised funds, ensuring they are used solely for designated purposes [3][4]. Regulatory Compliance - The agreement aligns with relevant laws and regulations, including the Shanghai Stock Exchange's self-regulatory guidelines, to protect investor rights [4][5]. Monitoring and Reporting - The underwriter is responsible for ongoing supervision of the fund usage, including site investigations and documentation requests, to ensure compliance with the agreement [4][5].

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-044 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于增设募集资金专户并签署募集资金专户存储 三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，公司向不特定对象共计发行 440.00 万张，每张面值为人民币 100 元，按面 值发行。本次发行的募集资金总额为 440,000,000.00 元，扣除相关发行费用 7,508,492.65 元，实际募集资金净额 432,491,507.35 元。 上述募集资金已全部到位，并由天健会计师事务所（特殊普通合伙）于 2022 年 7 月 4 日对本次发行的资金到账情况进行了审验，出具了《广州洁特生物过滤 股份有限公司向不特定对象发行可转换公司债券募 ...

目 录 | 、关于营业收入的问题…………………………………………………………… 第 1-14 页 | | --- | | 二、关于成本和毛利率变动 | | 三、关于应收账款的问题 …………………………………………………… 第 19―23 页 | | 四、关于存货的问题………………………………………………………… 第 23―31 页 | | 五、关于其他的问题…………………………………………………… 第 31—37 页 | | 六、资质证书复印件 …………… 第 38-41 页 | 监管问询函专项说明 天健函〔 2025 〕7–71 号 (一) 以表格形式列示不同类型产品的主要产品销售收入、销量、单价及同 比变化情况,并结合同行业可比公司情况,分析生物培养类、液体处理类产品收 入大幅增长的原因 诚信 公正 务实 专业 第1页 共41页 1. 不同类型产品的主要产品销售收入、销量、单价及同比变化情况 (1) 公司 2024 年主要产品销售收入、销量、单价及同比变化情况如下: 上海证券交易所科创板公司管理部: 由广州洁特生物过滤股份有限公司(以下简称洁特生物公司或公司)转来的 《关于广州洁特生物过滤股份有限公司 2 ...

Core Viewpoint - The company received an inquiry letter regarding its 2024 annual report from the Shanghai Stock Exchange, which it took seriously and responded to with detailed analyses and clarifications on various financial aspects [1]. Revenue Analysis - In 2024, the company achieved a total revenue of 559 million yuan, with biological culture revenue at 172 million yuan (up 9.08%) and liquid handling revenue at 337 million yuan (up 22.64%) [2][6]. - Overseas revenue reached 351 million yuan, accounting for 63% of total revenue, with a year-on-year increase of 23.50% [2][6]. - The gross profit margin for overseas sales was 43.31%, higher than the domestic margin of 37.54% [2]. Product Sales Breakdown - The sales revenue for liquid handling products significantly contributed to the overall revenue growth, with a notable increase from pipette products, which alone accounted for 30.64% of the total revenue increase [6][11]. - The average selling price of major products increased in 2024 due to price adjustments and a higher proportion of high-value products sold [10][11]. Customer Sales Information - The top five customers for both domestic and overseas sales remained stable, with no significant changes in relationships or sales dynamics [14][23]. - The sales collection rate for domestic customers reached 72.58% by the end of 2024, improving to 100% by May 31, 2025 [14][23]. Third-Party Data Verification - The company matched its export tax refund declarations with actual overseas revenue, showing a minimal discrepancy of -0.67% [23][24]. - The foreign exchange administration's collection data also showed a small difference of 1.84% compared to actual overseas revenue, indicating reliable revenue reporting [23][24].